Medical University Of Vienna
Vienna, Austria
Recruiting
Study on the Immune Response and Safety of an RSV Vaccine in Immunocompromised Patients Aged 18 and Older Using Arexvy and Saline
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying the effects of a vaccine for Respiratory Syncytial Virus (RSV), a virus that can cause respiratory infections, especially in people with weakened immune systems. The treatment being tested is called Arexvy, which is a vaccine designed to help the body build a defense against RSV. The study will also use saline, a simple saltwater solution, as a comparison.
The purpose of the study is to evaluate how the immune system responds to one or two doses of the Arexvy vaccine in people who have weakened immune systems and are 18 years or older. Participants will receive the vaccine through an injection into the muscle. The study will monitor the immune response by measuring specific antibodies, which are proteins the body makes to fight infections, over a period of time. The study will also look at the safety of the vaccine by checking for any side effects that might occur after the injections.
Participants will be observed for changes in their immune response and any side effects for up to 12 months after receiving the vaccine. The study aims to understand how well the vaccine works in boosting the immune system's ability to fight RSV and to ensure it is safe for use in people with compromised immune systems. This information will help in developing better protection against RSV for those who are most at risk.
The research process
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
8 criteria
- Participants must be at least 18 years old.
- Participants must have a condition related to the Respiratory syncytial virus.
- Participants must be able to understand and follow the study requirements, as judged by the study doctor.
- Participants must be able to provide written consent before joining the study and before any study-specific procedures are done.
- Female participants who can have children must use effective birth control starting one month before the first vaccine dose and continue for at least one month after the last vaccine dose. They must also have a negative pregnancy test on the day of the first vaccination.
- Female participants who cannot have children can join the study. This includes women who have had a hysterectomy (surgical removal of the uterus) or are post-menopausal (have stopped having periods).
- Participants living in the community or in an assisted-living facility with minimal help can join, as long as they can take care of themselves and perform daily activities.
- Participants with long-term medical conditions, whether they are receiving treatment or not, can join if the study doctor considers them to be medically stable.
Who cannot join the trial?
4 criteria
- Patients who are not immunocompromised. This means your immune system is not weakened or less able to fight infections.
- Patients under 18 years of age.
- Patients who have not received the first dose of the Arexvy vaccine.
- Patients who are not willing to receive a second dose of the Arexvy vaccine.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Verified
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
RecruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
Arexvy is a vaccine designed to protect against respiratory syncytial virus (RSV). It works by helping your immune system recognize and fight the virus if you are exposed to it. This vaccine is especially important for people with weakened immune systems, as they are more vulnerable to infections. In this study, researchers are looking at how well the vaccine works after one or two doses in people who are 18 years or older and have compromised immune systems. The goal is to see if the second dose provides a stronger immune response compared to just one dose.
What is already known about the treatment
Arexvy – Arexvy is administered as an injection, typically given in a healthcare setting. It is currently being studied in clinical trials, particularly for its effects on the immune response in immunocompromised patients aged 18 and older. The main therapeutic use of Arexvy is to protect against respiratory syncytial virus (RSV), a common virus that can cause serious respiratory illness. At the molecular level, Arexvy works by stimulating the body's immune system to produce antibodies and activate immune cells that target and neutralize the RSV virus. It is classified as a vaccine, specifically designed to enhance the immune response against RSV.
Investigated diseases
Respiratory Syncytial Virus – Respiratory Syncytial Virus (RSV) is a common virus that infects the respiratory tract, particularly affecting the lungs and breathing passages. It typically begins with symptoms similar to a mild cold, such as a runny nose, cough, and fever. As the infection progresses, it can lead to more severe respiratory issues, especially in infants and older adults, including bronchiolitis and pneumonia. The virus spreads through droplets from coughs or sneezes and can survive on surfaces, making it highly contagious. In most cases, symptoms resolve within one to two weeks, but the virus can cause significant discomfort and breathing difficulties during this period. RSV is a seasonal virus, with outbreaks commonly occurring in the fall and winter months.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-513187-25-00Protocol codeISPTM-RSV-001Estimated enrolment200 patientsSponsorMedical University Of Vienna
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?